Skip to Main Content

Print | Bookmark | Font Size: + |

LCD & Medical Policy Stakeholder Meetings

Compliance Officer Meetings

Closed to members & invited guests.

State Date & Time Location
J15 KY/OH February 25, 2025
2:30 – 3:30 pm ET (1:30 – 2:30 pm CT)
Microsoft Teams

CAC Meetings

Contractor Advisory Committee (CAC) meetings are for the purpose of discussing literature related to proposed Local Coverage Determinations (LCDs) before they're developed.

CAC members serve in an advisory capacity. All meetings are open to the public to attend and observe.

Currently, there are no scheduled meetings.

See Prior CAC Meetings below.

Open Meetings

Open Meetings are for the purpose of discussing new proposed (draft) LCDs or the revised portion of a proposed LCD in the 45-day open comment period. These meetings are not a forum to discuss specific claims, the submission of new drugs or indications, or to market forthcoming drugs or medical devices.

Open to the public.

State Date & Time Location Agenda
J15 KY & OH June 10, 2025
4 – 5 pm ET (3 – 4 pm CT)
Microsoft Teams

Announcement

RegistrationExternal Website

Topics:

Proposed/Draft LCDs not released to final:

J15 KY/OH February 25, 2025
4 – 5 pm ET (3 – 4 pm CT)
Microsoft Teams Topics:
  • DL40056/DA59981 – Allergen Immunotherapy (AIT) with Subcutaneous Immunotherapy (SCIT)
  • Proposed/Draft LCDs not released to final:

See Prior Open Meetings below.

Provider Touch Point Meetings

Closed to members & invited guests.

State Date & Time Location
J15 KY & OH June 10, 2025
6 – 7 pm ET (5 – 6 pm CT)
Microsoft Teams

Prior CAC Meetings

Date Topic Details Documentation
02.03.2025 Peripheral Nerve Blocks and Ablations
10.17.2024 Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC)
07.15.2024 MolDX: Biomarker Risk Stratification Testing in DCIS
10.19.2023 Botulinum Toxins
08.16.2023 Cervical Fusion
05.25.2023 Non-Invasive Technology for Coronary Artery Plaque Analysis
04.27.2023 Trigger Point Injections
  • Multi-Jurisdictional Host: WPS Government Health Administrators (GHA)
02.28.2023 RPM and RTM for Non-Implantable Devices
  • Multi-Jurisdictional Host: Novitas and First Coast Service Options
01.05.2023 Micro-Invasive Glaucoma Surgery (MIGS)
11.09.2022 PET Scans for Inflammation and Infection
03.10.2022 Sacroiliac Joint Injections and Procedures
12.07.2021 MolDX: Predictive Testing to Guide Targeted Therapy Selection in Rheumatoid Arthritis
10.12.2021 MolDX: Molecular Testing for Risk Stratification of Upper Gastrointestinal Cancer
09.29.2021 Transcranial Magnetic Stimulation (TMS) for Obsessive-Compulsive Disorder (OCD)
05.12.2021 Amniotic Product Injections for Musculoskeletal Indications, Non-Wound
03.10.2021 Platelet Rich Plasma for Non-Wound Care
02.11.2021 Epidural Interventions for Chronic Pain Management
01.11.2021 Molecular Diagnostic Testing for Pathogens
11.18.2020 Electroretinography  
05.28.2020 Facet Joint and Medical Nerve Branch Procedures  
06.29.2019 Pharmacogenomics  
03.20.2019 Vertebral Augmentation  

Prior Open Meetings

State Date Topics Documentation
J15 KY & OH 02.25.2025
  • DL40056/DA59981 – Allergen Immunotherapy (AIT) with Subcutaneous Immunotherapy (SCIT)
J15 OH 10.30.2024
  • MolDX: Genetic Testing for Heritable Thoracic Aortic Disease (DL39938/DA59860)
  • MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative Neoplasms (DL4000/DA59919)
  • MolDX: Molecular Testing for Identification and Management of Hereditary Transthyretin Amyloidosis (DL39940/DA59862)
  • Intravertebral Disc Injections (Via Disc) 0627T (DL39958/DA59880)
  • Non-invasive Vascular (open to revised section only) (DL34045/DA56697)
J15 KY 10.29.2024
  • MolDX: Genetic Testing for Heritable Thoracic Aortic Disease (DL39938/DA59860)
  • MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative Neoplasms (DL4000/DA59919)
  • MolDX: Molecular Testing for Identification and Management of Hereditary Transthyretin Amyloidosis (DL39940/DA59862)
  • Intravertebral Disc Injections (Via Disc) 0627T (DL39958/DA59880)
  • Non-invasive Vascular (open to revised section only) (DL34045/DA56697)
J15 KY/OH 06.18.2024
  • DL37578/DA56491 – MIGS
  • DL39857/DA59726 – Botulinum Toxins
  • DL39840/DA59716 – Quantitative Coronary Plaque Analysis derived from Artificial Intelligence Enabled CT Based Quantitative Coronary Topography (AI-QTC)/Coronary Plaque Analysis (AI-CPA)
J15 KY/OH 05.16.2024
  • DL39756/DA59618 – Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers
  • DL39802/DA59682 – Minimally Invasive Arthrodesis of the Sacroiliac Joint (SIJ)
J15 KY/OH 02.13.2024
  • DL38773 – Facet Joint Interventions for Pain Management
  • DA58346 – Billing and Coding: Facet Joint Interventions for Pain Management
  • DL39741 – Cervical Fusion
  • DA 59608 – Billing and Coding: Cervical Fusion
J15 OH 11.08.2023
  • MolDX: Gene Expression Profile Tests for Decision-Making in Castration Resistant and Metastatic Prostate Cancers
  • MolDX: Molecular Biomarkers for Risk Stratification of Indeterminate Pulmonary Nodules Following Bronchoscopy
  • MolDX: Molecular Testing for Risk Stratification of Thyroid Nodules
  • MolDX: Molecular Testing for Solid Organ Allograft Rejection
  • Implantable Continuous Glucose Monitors (I-CGM)
  • Trigger Point Injections (TPI)
J15 KY 11.07.2023
  • MolDX: Gene Expression Profile Tests for Decision-Making in Castration Resistant and Metastatic Prostate Cancers
  • MolDX: Molecular Biomarkers for Risk Stratification of Indeterminate Pulmonary Nodules Following Bronchoscopy
  • MolDX: Molecular Testing for Risk Stratification of Thyroid Nodules
  • MolDX: Molecular Testing for Solid Organ Allograft Rejection
  • Implantable Continuous Glucose Monitors (I-CGM)
  • Trigger Point Injections (TPI)
J15 KY/OH 07.11.2023
  • Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound
  • Fluid Jet System in the Treatment of Benign Prostatic Hyperplasia (BPH)
  • Micro-Invasive Glaucoma Surgery (MIGS)MolDX: Molecular Biomarker Testing for Risk Stratification of Cutaneous Squamous Cell Carcinoma
J15 KY/OH 06.22.2023
  • Urinary Biomarkers for Chronic Pain Management
J15 KY/OH 05.17.2023
  • Urine Drug Testing
J15 KY/OH 02.21.2023
  • Cosmetic and Reconstructive Surgery
  • Positron Emission Tomography (PET) for Inflammation and Infection Special Histochemical Stains and Immunohistochemical Stains
  • Transthoracic Echocardiography (TTE)
J15 OH 10.26.2022
  • Allogenic Hematopoietic Cell Transplantation for Primary Refractory or Relapsed Hodgkin's and Non-Hodgkin's Lymphoma with B-cell or T-cell Origin
  • MolDX: Molecular Assays for the Diagnosis of Cutaneous Melanoma
  • MolDX: Molecular Biomarker Testing to Guide Targeted Therapy Selection in Rheumatoid Arthritis
  • Sacroiliac Joint Injections and Procedures
  • Skin Substitutes for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers
  • Transtelephonic Spirometry
  • Urine Drug Testing
J15 KY 10.25.2022
  • Allogenic Hematopoietic Cell Transplantation for Primary Refractory or Relapsed Hodgkin's and Non-Hodgkin's Lymphoma with B-cell or T-cell Origin
  • MolDX: Molecular Assays for the Diagnosis of Cutaneous Melanoma
  • MolDX: Molecular Biomarker Testing to Guide Targeted Therapy Selection in Rheumatoid Arthritis
  • Sacroiliac Joint Injections and Procedures
  • Skin Substitutes for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers
  • Transtelephonic Spirometry
  • Urine Drug Testing
J15 KY/OH 06.21.2022
  • MolDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia and Neoplasia
  • MolDX: Prognostic and Predictive Molecular Classifiers for Bladder Cancer
  • Prostate Cancer Detection with IsoPSA™
  • Transcranial Magnetic Stimulation (TMS)
J15 KY/OH 02.22.2022
  • Non-Invasive Fractional Flow Reserve (FFR) for Stable Ischemic Heart Disease
J15 KY/OH 10.13.2021
  • Colon Capsule Endoscopy (CCE)
  • Prostate Cancer Detection with IsoPSA™
J15 KY/OH 07.13.2021
  • Epidural Procedures for Pain Management
  • MolDX: Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer
  • MolDX: Melanoma Risk Stratification Molecular Testing
  • MolDX: Multiplex Nucleic Acid Amplification Test (NAAT) Panels for Infectious Disease Testing
  • MolDX: Next-Generation Sequencing Lab-Developed Tests for Inherited Cancer Syndromes
J15 KY/OH 02.23.2021
  • Off-Label Use of Rituximab and Rituximab Biosimilars
  • Percutaneous Vertebral Augmentation (PVA) for Osteoporotic Vertebral Compression Fracture (VCF)
J15 KY/OH 10.13.2020
  • Non-Invasive Flow Reserve (FFR) for Stable Ischemic Heart Disease
J15 KY/OH 10.13.2020
  • Colon Capsule Endoscopy (CCE)
  • Controlled Substance Monitoring and Drugs of Abuse Testing
  • Magnetic Resonance Guided Focused Ultrasound Surgery System (MRgFUS) for the Treatment of Neurologic Conditions
  • MolDX: Minimal Residual Disease Testing (MRDT) for Cancer
J15 KY/OH 10.13.2020
  • Facet Joint Interventions for Pain Management
J15 KY/OH 02.18.2020
  • Vitamin D Assay Testing (L33996) Reconsideration
J15 OH 10.30.2019
  • Open Draft/Revised LCD Discussion
J15 KY 10.29.2019
  • Open Draft/Revised LCD Discussion
J15 KY/OH 06.18.2019
  • Open Draft/Revised LCD Discussion
J15 KY/OH 05.07.2019
  • Drug Interaction Testing and Multiple MolDX Draft Policies
J15 KY/OH 02.12.2019
  • MolDX: DecisionDx – Melanoma

Updated: 05.19.2025

spacer

26 Century Blvd Ste ST610, Nashville, TN 37214-3685 © CGS Administrators, LLC. All Rights Reserved